Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

starr-2-advert.gif

Recruiting now!

THE COPD STARR 2 TRIAL

Delivering personalised care in the management of exacerbations of chronic obstructive pulmonary disease: A multi-centre randomised clinical trial

Ethics Ref: 17/LO/1135

EudraCT Number: 2017-001586-24

Background: Acute exacerbations of chronic obstructive pulmonary disease (AE-COPD) are debilitating and a major NHS Burden. Treat guidelines recommend oral steroids and antibiotics but failure to respond to is a common, AE-COPD aetiology and response to treatment is varied. Current ‘one-size-fits-all’ approaches are unsatisfactory.

Hypothesis: A personalised stratified treatment approach in AE-COPD in primary care using near-patient testing to derive phenotypes of COPD is superior to current strategies.

Study Deign: Double-blinded randomised placebo control study

Expected outcomes: Treatment failure rates are reduced in AE-COPD receiving phenotype-specific-near-patient testing directed therapy.

Anticipated benefits: Health economics benefit and guideline changes in AE-COPD management.

Who to contact if you want more information

Professor Mona Bafadhel (study Doctor)                             Tel 01865 612898

Joanne Davies and Helen Jeffers (study Nurses)                  Tel 07769 280289/07554 436726